Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Belimumab in Refractory SLE
NCT02284984Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2014
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and belimumab in systemic lupus erythematosus (SLE), sponsored by Leiden University Medical Center. Primary endpoint: Reduction of pathogenic autoantibodies at 24 weeks. Started Mar 2014; status: completed.
02
Drugs
rituximabbelimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02284984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02284984.